Research teams, sponsors and CROs comparing data collection for clinical trials, from focused participant-centered studies to complex multi-site protocols.
Scope Dedicated EDC systems and participant-centered clinical-trial data collection are compared by their documented capabilities. Whether a participant-centered platform also needs a dedicated EDC depends on in-visit data entry, clinical queries, coding, verification and database-management requirements, rather than study size or trial phase alone.
These notes describe the products in the EDC guide.
OpenClinica
Best for
Academic groups, CROs and small sponsors that want published per-study prices and standards-based data exchange.
What to consider
OpenClinica is the only commercial EDC here with public list prices, and it documents an ODM-based REST API. It has fewer native modules than the enterprise suites, and Everest Group rated it a Major Contender, not a Leader, in 2024.
Academic and non-profit teams running investigator-initiated studies, as a free baseline.
What to consider
REDCap is the free academic baseline, with open data standards and very wide adoption. It comes without vendor support, its Part 11 status depends on each institution, and sponsors and CROs cannot license it.
Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.
Expand a feature definition or support note for context and its original source.
OpenClinica vs REDCap (EDC): category feature evidence and sources. Products are not ranked.
Category feature
OpenClinica
REDCap
Track record in regulated multi-site trialsFeature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
OpenClinica
Supported
OpenClinica says its technology has powered over 15,000 studies and more than three million patients.
The REDCap Consortium lists 8,526 institutions in 167 countries and 2.9M projects, but REDCap is licensed to non-profits and its use is concentrated in academic research.
Trial standards and ISO/SOC claims are stated; public certificate or report access is not established.
REDCap
Supported
Vanderbilt says REDCap can be installed for 21 CFR Part 11 compliance, but this depends on each institution's setup; Penn Medicine, for example, states its REDCap is not Part 11-compliant.